Pharma Leadership Forum 2021: Building a Vision for the Future – Accelerating Drug Discovery for a Better Tomorrow Read more
Empagliflozin reduces hospitalisation risk for heart-failure and cardiovascular death by 21 per cent, shows Boehringer Ingelheim’s Emperor-Preserved trial Read more